EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Other Events
Item 8.01
On September 23, 2019, EyeGate Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| (d) | Exhibits. |
The Company hereby files the following exhibit:
| 99.1 | Press Release of the Company, dated as of September 23, 2019. |
EYEGATE PHARMACEUTICALS INC Exhibit
EX-99.1 2 tv529865_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 EyeGate Pharma Regains Nasdaq Listing Compliance WALTHAM,…
To view the full exhibit click here
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
